Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inoperable Disease Clear all
Completed Phase 2 Interventional Results available

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NCT00589784
View directory record Official record
Conditions
CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions
Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 22, 2026, 2:21 PM EDT
Terminated Phase 1 Interventional

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01411098
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, cisplatin, etoposide
Radiation · Drug
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 22, 2026, 2:21 PM EDT
Not listed Phase 2 Interventional

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

NCT03567720
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
tavokinogene telseplasmid, Pembrolizumab, Immunopulse, nab paclitaxel, gemcitabine plus carboplatin
Biological · Device · Drug
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 1Phase 2 Interventional

Combination With Gemcitabine in Advanced Pancreatic Cancer

NCT01251640
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
BAY86-9766+Gemcitabine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 99 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Pittsfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 22, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
80
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

NCT00909402
View directory record Official record
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
BMS-833923, Cisplatin, Capecitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional

Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer

NCT00322751
View directory record Official record
Conditions
Lung Cancer
Interventions
Topotecan
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

NCT00983307
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
Erlotinib, Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dunmore, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

NCT03513952
View directory record Official record
Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography and Computed Tomography Scan
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 22, 2026, 2:21 PM EDT
Not listed Early Phase 1 Interventional

Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

NCT02619448
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Paclitaxel, 70 Gy in 20 fractions over 4 weeks
Drug · Radiation
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

NCT00087438
View directory record Official record
Conditions
Lung Cancer
Interventions
stereotactic body radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Rochester, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

NCT00166543
View directory record Official record
Conditions
Breast Cancer
Interventions
TAS-108
Drug
Lead sponsor
SRI International
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Sep 22, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

NCT00365183
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Motexafin gadolinium and pemetrexed
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Huntington Beach, California • Long Beach, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 22, 2026, 2:21 PM EDT
Active, not recruiting Phase 1 Interventional

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

NCT04676477
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
HER3-DXd, Osimertinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Santa Monica, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 22, 2026, 2:21 PM EDT
Not listed Phase 2 Interventional

Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer

NCT00178763
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Heckel Infrared Radiant Heat Device, cisplatin, gemcitabine, interferon-alpha, thermochemotherapy
Device · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Sep 22, 2026, 2:21 PM EDT
Terminated Not applicable Interventional

Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer

NCT00003851
View directory record Official record
Conditions
Malnutrition, Pancreatic Cancer
Interventions
proteolytic enzymes, gemcitabine hydrochloride, Gonzalez regimen
Biological · Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

NCT00102505
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Sep 22, 2026, 2:21 PM EDT
Withdrawn Phase 1 Interventional

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

NCT05600582
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
CodaLytic
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 22, 2026, 2:21 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 22, 2026, 2:21 PM EDT
Approved For Marketing No phase listed Expanded access

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

NCT03259633
View directory record Official record
Conditions
NF type1 With Inoperable Plexiform Neurofibromas
Interventions
Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 130 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

NCT03125902
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Atezolizumab Placebo, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 22, 2026, 2:21 PM EDT
Recruiting Phase 1 Interventional

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811
View directory record Official record
Conditions
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
Interventions
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

NCT01899989
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 22, 2026, 2:21 PM EDT